screening for gynecological cancer
_______________________________________________________________
_______________________________________________________________
Report Information from ProQuest
May 27 2014 19:59
Created by My Research account: SMOK1024 (alonzo strom)
_______________________________________________________________
27 May 2014
ProQuest
Table of contents
1. Screening for gynecological cancers............................................................................................................ 1
Bibliography...................................................................................................................................................... 28
27 May 2014
ii
ProQuest
Document 1 of 1
Screening for gynecological cancers
Author: Kalsi, Jatinderpal K; Manchanda, Ranjit; Menon, Usha
ProQuest document link
Abstract: An estimated 17% of all new cancers in women worldwide are due to cancers of the cervix, the ovary and the uterus. Together, these cancers account for 14.6% of all female cancer deaths. This is a significant societal and economic burden, which can be limited through cancer screening. In the developed world, marked reductions of 50-90% in disease rates have been observed as a result of cervical cancer screening. By contrast, in developing countries, where more than 85% of all new cases and deaths from this cancer are reported, significant challenges need to be overcome. Although cytology remains a key component of cervical screening, the newer molecular tests offer a more targeted, risk-attuned approach. The situation for the other two gynecological cancers is different. The case for ovarian cancer screening has yet to be made with the results of key screening trials in high- and low-risk populations still pending. Screening for endometrial cancer is traditionally not advocated as women become symptomatic during the earlier, treatable stages of disease.
However, consideration of screening options for these two
_______________________________________________________________
Report Information from ProQuest
May 27 2014 19:59
Created by My Research account: SMOK1024 (alonzo strom)
_______________________________________________________________
27 May 2014
ProQuest
Table of contents
1. Screening for gynecological cancers............................................................................................................ 1
Bibliography...................................................................................................................................................... 28
27 May 2014
ii
ProQuest
Document 1 of 1
Screening for gynecological cancers
Author: Kalsi, Jatinderpal K; Manchanda, Ranjit; Menon, Usha
ProQuest document link
Abstract: An estimated 17% of all new cancers in women worldwide are due to cancers of the cervix, the ovary and the uterus. Together, these cancers account for 14.6% of all female cancer deaths. This is a significant societal and economic burden, which can be limited through cancer screening. In the developed world, marked reductions of 50-90% in disease rates have been observed as a result of cervical cancer screening. By contrast, in developing countries, where more than 85% of all new cases and deaths from this cancer are reported, significant challenges need to be overcome. Although cytology remains a key component of cervical screening, the newer molecular tests offer a more targeted, risk-attuned approach. The situation for the other two gynecological cancers is different. The case for ovarian cancer screening has yet to be made with the results of key screening trials in high- and low-risk populations still pending. Screening for endometrial cancer is traditionally not advocated as women become symptomatic during the earlier, treatable stages of disease.
However, consideration of screening options for these two
References: 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J. Clin. 61(2), 69-90 (2011). Oncol. 9(3), 131-132 (2012). Clin. 62(3), 147-172 (2012). 6 Wilson JMG, Junger G. Principles and Practice of Screening for Disease . Public Health Paper 34. WHO, Geneva, Switzerland (1968). Berlin, Germany 194-252 (2011). (2008). 9 zur Hausen H. Papillomaviruses in the causation of human cancers -a brief historical account. Virology 384(2), 260-265 (2009). Ann. Intern. Med. 155(10), 698-705 (2011). Ann. Intern. Med. 155(10), 698-705 (2011). cancer. N. Engl. J. Med. 348(6), 518-527 (2003). Group. A review of human carcinogens -part B: biological agents. Lancet Oncol. 10(4), 321-322 (2009). worldwide study. Lancet Oncol. 11(11), 1048-1056 (2010). 17 Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10(8), 550-560 (2010). Pathol. Lab. Med. 121(3), 211-224 (1997). 21 Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am. J. Epidemiol. 141(7), 680-689 (1995). 22 Hatem F, Wilbur DC. High grade squamous cervical lesions following negative Papanicolaou smears: falsenegative cervical cytology or rapid progression. Diagn. Cytopathol. 12(2), 135-141 (1995). Cancer Cytopathol. 120(2), 87-96 (2012). 25 ACOG Practice Bulletin. Cervical cytology screening. Number 45, August 2003. Int. J. Gynaecol. Obstet. 83, 237-247 (2003). (2008). 32 NHSCSP Publication No. 1. Achievable Standards, Benchmarks for Reporting, and Criteria for Evaluating Cervical Cytopathology (3rd Edition) (2012). 19(4), 517-529 (2005).